Established in 2001, Fusion Antibodies is a Collaborative Research Organisation (CRO) with its headquarters in Northern Ireland. We are world leaders in antibody development services specializing in the discovery, engineering and supply of pre-clinical biologics through to clinical Cell Line Development. Having guided hundreds of projects through critical pre-clinical stages, our expertise is proven time and time again as we strive to bring about a positive change in the healthcare industry.
Fusion has developed a number of unique, proprietary technology platforms. Our suite of development capabilities include:
• Antibody humanization (CDRx™)
• Affinity maturation (RAMP™)
• Protein engineering
• Discovery (mouse hybridoma and rabbit B cell approaches)
• Protein production – CHO and other mammalian systems
• Cell Line Development – cGMP ready mammalian cell lines (up to 8 g/L)
• Expert scientific & technical advisory services
• Bespoke & collaborative large-scale research and development programs
Our approach to engineering and optimization is often to harnesses the power of the natural somatic hypermutation space. Fusion offers flexibility and agility while delivering clinical candidates with a focus on developability, manufacturability and function.
 |
Antibody engineering and humanization services Fusion Antibodies offer as a service the humanization of monoclonal antibodies. Contact us to find out more about what Humanization can do for your therapeutic targets. |
 |
Custom expression and purification of recombinant proteins We are experts at the expression and purification of recombinant proteins from both E. coli and mammalian vectors. We specialize in protein purification using a range of techniques, including purification of insoluble proteins from inclusion bodies. |
 |
Cell line development |